InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
12
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Graham G. Walmsley, Director. Director active across 2 companies, notably Akero Therapeutics, Inc.. In total, 21 filings have been logged. Split: 12 buys · 4 sells. Total volume traded: €76.1m. History available since 19 May 2023. The latest transaction was disclosed on 8 October 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Graham G. Walmsley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
93,000 sharesCommon StockSEC:0001193125-25-312122:0
1,200,000 sharesCommon StockSEC:0001193125-25-312122:1
9,398 sharesCommon StockSEC:0001193125-25-312122:2
26,000 shares@ US$23.021.2% of flowCommon StockSEC:0001193125-25-237295:0
9,398 shares0Common StockSEC:0000950170-25-082306:0
91,309 shares@ US$44.7478.7% of flowCommon StockSEC:0000950170-25-046271:0
Canonical exit: 23 Jun 2025 (T+90)
200,000 shares@ US$48.0021.2% of flowCommon StockSEC:0000950170-25-016559:0
Canonical exit: 30 Apr 2025 (T+90)
700,761 shares@ US$6.7513.8% of flowCommon StockSEC:0000935836-24-000764:0
700,761 shares@ US$6.7513.7% of flowCommon StockSEC:0000935836-24-000763:0
700,000 shares@ US$14.8529.2% of flowCommon StockSEC:0000935836-24-000744:0
700,000 shares@ US$14.8529.2% of flowCommon StockSEC:0000935836-24-000425:0
508,130 shares@ US$9.8414.2% of flowCommon StockSEC:0000935836-23-000733:0
Canonical exit: 11 Dec 2023 (T+90)
50,000 shares@ US$19.80482.1% of flowCommon StockSEC:0000950170-23-069509:0
Canonical exit: 7 Mar 2024 (T+90)
50,000 shares@ US$16.89671.8% of flowCommon StockSEC:0000950170-23-067951:0
Canonical exit: 28 Feb 2024 (T+90)
50,000 shares@ US$16.99461.8% of flowCommon StockSEC:0000950170-23-067951:1
Canonical exit: 29 Feb 2024 (T+90)
25,000 shares@ US$42.0592.2% of flowCommon StockSEC:0000950170-23-041440:0
Canonical exit: 6 Nov 2023 (T+90)
30,000 shares@ US$42.69032.7% of flowCommon StockSEC:0000950170-23-036694:0
Canonical exit: 26 Oct 2023 (T+90)
25,000 shares@ US$43.2612.3% of flowCommon StockSEC:0000950170-23-036694:1
Canonical exit: 30 Oct 2023 (T+90)
400,000 shares@ US$26.0023.9% of flowCommon StockSEC:0000899243-23-015665:0
Canonical exit: 18 Dec 2022 (T+90)
120,000 shares@ US$42.0010.8% of flowCommon StockSEC:0000950170-23-023738:1
Canonical exit: 17 Aug 2023 (T+90)
400,000 shares@ US$26.0022.5% of flowCommon StockSEC:0000950170-23-023738:0
Canonical exit: 21 Aug 2023 (T+90)
21 of 21 declarations
About Graham G. Walmsley
Graham G. Walmsley is a Director at Akero Therapeutics, Inc. and Olema Pharmaceuticals, Inc. The 21 filings in the recent sample run from 2023-05-23 to 2025-12-09, with purchases totaling EUR 47998740 and sales totaling EUR 28118691, and the modal transaction nature is Acquisition.
